Nies, Richard J. ORCID: 0000-0002-1336-6031, Ney, Svenja, Kindermann, Ingrid, Bewarder, Yvonne, Zimmer, Angela, Knebel, Fabian, Hahn, Katrin, Spethmann, Sebastian, Luedike, Peter, Michel, Lars, Rassaf, Tienush, Papathanasiou, Maria, Störk, Stefan, Cejka, Vladimir, Polzin, Amin, Voss, Fabian, Kelm, Malte, Unsöld, Bernhard, Meindl, Christine, Paulus, Michael, Yilmaz, Ali, Chamling, Bishwas, Morbach, Caroline and Pfister, Roman ORCID: 0000-0001-8259-1737 (2025). Real-World Characteristics and Treatment of Cardiac Transthyretin Amyloidosis: A Multicentre, Observational Study. ESC Heart Failure, 12 (2). pp. 1203-1216. Wiley. ISSN 2055-5822

[thumbnail of ESC Heart Failure - 2024 - Nies - Real‐world characteristics and treatment of cardiac transthyretin amyloidosis A.pdf] PDF
ESC Heart Failure - 2024 - Nies - Real‐world characteristics and treatment of cardiac transthyretin amyloidosis A.pdf
Bereitstellung unter der CC-Lizenz: Creative Commons Attribution Non-commercial No Derivatives.

Download (1MB)
Identification Number:10.1002/ehf2.15126

Abstract

Aims: Data on the clinical profiles of patients with transthyretin amyloidosis cardiomyopathy (ATTR-CM) in the post-approval era of tafamidis 61 mg are lacking. Study aims were characterization of contemporary ATTR-CM patients, analysis of potential eligibility for the ‘Transthyretin Amyloidosis Cardiomyopathy Clinical Trial’ (ATTR-ACT) and identification of factors associated with the decision on tafamidis 61 mg treatment. Methods and results: This retrospective study analysed ATTR-CM patients seen at eight University Hospitals in the first year after approval of tafamidis 61 mg for ATTR-CM in Germany (April 2020 to March 2021). The cohort comprised 366 patients (median age 79 [74; 82] years, 84% male), with 47% and 45% of the cohort being in National Amyloidosis Centre ATTR stage ≥ II and NYHA class ≥ III, respectively. Sixty-four per cent of patients met key eligibility criteria of the pivotal ATTR-ACT. In recently diagnosed patients (58% with diagnosis ≤6 months), the rate of variant ATTR was significantly lower than in patients diagnosed more than 6 months ago (9.3% vs. 19.7%). Of the 293 patients without prior ATTR specific treatment, tafamidis 61 mg was newly initiated in 77%. Patients with tafamidis 61 mg treatment were significantly younger, were more often eligible for ATTR-ACT, had lower NYHA class and higher serum albumin levels. These variables explained 16% of the variance of treatment decision. Unadjusted survival was higher in patients with than those without treatment (1-year survival 98.6% vs. 87.3%, P < 0.001). Conclusions: Wild-type ATTR was the primary aetiology amongst contemporary ATTR-CM patients and almost two-thirds of patients were in an advanced disease stage. Clinical profiles of 64% of patients in routine care matched those of the ATTR-ACT. Further effort is needed to detect patients at an earlier disease stage and to validate criteria justifying treatment initiation.

Item Type: Article
Creators:
Creators
Email
ORCID
ORCID Put Code
Nies, Richard J.
UNSPECIFIED
UNSPECIFIED
Ney, Svenja
UNSPECIFIED
UNSPECIFIED
UNSPECIFIED
Kindermann, Ingrid
UNSPECIFIED
UNSPECIFIED
UNSPECIFIED
Bewarder, Yvonne
UNSPECIFIED
UNSPECIFIED
UNSPECIFIED
Zimmer, Angela
UNSPECIFIED
UNSPECIFIED
UNSPECIFIED
Knebel, Fabian
UNSPECIFIED
UNSPECIFIED
UNSPECIFIED
Hahn, Katrin
UNSPECIFIED
UNSPECIFIED
UNSPECIFIED
Spethmann, Sebastian
UNSPECIFIED
UNSPECIFIED
UNSPECIFIED
Luedike, Peter
UNSPECIFIED
UNSPECIFIED
UNSPECIFIED
Michel, Lars
UNSPECIFIED
UNSPECIFIED
UNSPECIFIED
Rassaf, Tienush
UNSPECIFIED
UNSPECIFIED
UNSPECIFIED
Papathanasiou, Maria
UNSPECIFIED
UNSPECIFIED
UNSPECIFIED
Störk, Stefan
UNSPECIFIED
UNSPECIFIED
UNSPECIFIED
Cejka, Vladimir
UNSPECIFIED
UNSPECIFIED
UNSPECIFIED
Polzin, Amin
UNSPECIFIED
UNSPECIFIED
UNSPECIFIED
Voss, Fabian
UNSPECIFIED
UNSPECIFIED
UNSPECIFIED
Kelm, Malte
UNSPECIFIED
UNSPECIFIED
UNSPECIFIED
Unsöld, Bernhard
UNSPECIFIED
UNSPECIFIED
UNSPECIFIED
Meindl, Christine
UNSPECIFIED
UNSPECIFIED
UNSPECIFIED
Paulus, Michael
UNSPECIFIED
UNSPECIFIED
UNSPECIFIED
Yilmaz, Ali
UNSPECIFIED
UNSPECIFIED
UNSPECIFIED
Chamling, Bishwas
UNSPECIFIED
UNSPECIFIED
UNSPECIFIED
Morbach, Caroline
UNSPECIFIED
UNSPECIFIED
UNSPECIFIED
Pfister, Roman
UNSPECIFIED
UNSPECIFIED
URN: urn:nbn:de:hbz:38-816568
Identification Number: 10.1002/ehf2.15126
Journal or Publication Title: ESC Heart Failure
Volume: 12
Number: 2
Page Range: pp. 1203-1216
Number of Pages: 14
Date: 1 April 2025
Publisher: Wiley
ISSN: 2055-5822
Language: English
Faculty: Faculty of Medicine
Divisions: Faculty of Medicine > Innere Medizin > Klinik III für Innere Medizin - Kardiologie, Pneumologie, Angiologie und internistische Intensivmedizin
Subjects: Medical sciences Medicine
Uncontrolled Keywords:
Keywords
Language
rdiac amyloidosis; Cardiomyopathy; Heart failure; TTR; Transthyretin; Tafamidis
English
['eprint_fieldname_oa_funders' not defined]: Publikationsfonds UzK
Refereed: Yes
URI: http://kups.ub.uni-koeln.de/id/eprint/81656

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item